SynAct Pharma AB (“SynAct”) today announced that the members of the Board of Directors Charlotte Edenius and Lars Adlersson have decided to leave their positions in the company. SynAct will shortly convene an Extraordinary General Meeting for the election of new members of the Board of Directors, and the work to find suitable candidates begins immediately.
members of the Board of Directors Charlotte Edenius and Lars Adlersson believe that the time is right to pass on the baton – SynAct has successfully completed the phase I programme with candidate drug AP1189 and has started planning for phase II studies.
Chairman of the Board Torbjørn Bjerke comments:
“With their complete commitment, Charlotte and Lars have made a valuable contribution to the development of SynAct into the biotech company it is today. I would like to thank them very much for all their hard work. We are now starting the work of finding two suitable replacements to further develop SynAct and lead the continued clinical development of candidate drug AP1189.”
Charlotte Edenius and Lars Adlersson will remain as members of the Board of Directors until the planned Extraordinary General Meeting.
This is information that SynAct Pharma AB is obliged to disclose under the EU’s market abuse regulation. The information was submitted by the above contact person for publication on 13th February 2019.
For further information about SynAct Pharma AB, please contact:
Chairman of the Board, SynAct Pharma AB
E-mail: [email protected]